Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

GSK, Innoviva seek EU nod for triple combo inhaled therapy

December 5, 2016 By Sarah Faulkner

GSK, Innoviva seek EU nod for triple combo inhaled therapyGlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said last week that they filed a regulatory submission with the European Medicines Agency for the once-daily, triple-combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) for patients with chronic obstructive pulmonary disease. Last month, the companies submitted a new drug application for the inhaled therapy to the FDA for approval in the U.S.

The triple combination therapy is made up of 3 drugs – an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-adrenergic agonist. The treatment is delivered once a day using GSK’s Ellipta dry powder inhaler. The regulatory submission is backed by clinical data that includes the phase III Fulfil study, which compared once daily FF/UMEC/VI with AstraZeneca‘s (NYSE:AZN) twice daily Symbicort Turbohaler in patients with advanced COPD. The triple combo therapy demonstrated improved lung function and statistically significant reductions in exacerbations.

“Many patients with COPD are already at an advanced stage when they are diagnosed. Prescribing patterns show the importance of having a range of options available to meet the differing needs of individual patients,” GSK R&D head of respiratory therapy area unit Dave Allen said in prepared remarks. “An approval of our closed triple therapy in Europe would complement our portfolio of inhaled therapies designed for once-daily dosing in a single inhaler, offering patients a convenient, alternative option.”

“The EU filing of the closed triple combination is the latest development in our long-standing collaboration with GSK,” Innoviva CEO Mike Aguiar added. “If approved, FF/UMEC/VI as once daily triple combination in a single inhaler could be a meaningful addition to the treatment options available for advanced COPD patients.”

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Respiratory Tagged With: AstraZeneca plc, GlaxoSmithKline plc, Innoviva

IN CASE YOU MISSED IT

  • FDA approves Tandem Diabetes’ advanced hybrid closed-loop controller
  • Senate confirms Dr. Stephen Hahn to lead FDA
  • 3M to sell drug-delivery biz to Altaris Capital Partners for $650m
  • Medicina recalls IV Luer Slip syringes
  • Eitan Group signs service agreement with Integrated Medical Systems
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS